Cervical cancer deaths forecast to rise 39% by 2050: what lowers the risk

A Global Burden of Disease study projects 522,000 deaths a year by 2050, with sub-Saharan Africa hit hardest. Countries that vaccinate girls against HPV and screen women regularly are already seeing cases fall.

5 min read

A Global Burden of Disease study projects 522,000 deaths a year by 2050, with sub-Saharan Africa hit hardest. Countries that vaccinate girls against HPV and screen women regularly are already seeing cases fall.

Cervical cancer will kill more women each year unless countries widen prevention, according to a new Global Burden of Disease (GBD) study. Writing in Nature Medicine, the GBD 2023 Cervical Cancer Collaborators forecast that annual deaths will rise by 39.3% by 2050. New cases are projected to grow by 20.2%.

The study estimated 887,000 new cases and 369,000 deaths worldwide in 2023. By 2050, the forecast reaches about 1.08 million cases and 522,000 deaths a year. The paper, led by Natalie Pritchett and Lisa Force, was published on 2 November.

Sub-Saharan Africa faces the steepest rise

Sub-Saharan Africa already has the highest incidence and mortality of any region. There, cases could rise by 88.7% and deaths by 95.4% by 2050, reaching about 206,000 deaths a year. In 2023, age-standardised incidence in low-income countries was more than four times the rate in high-income countries. Mortality was more than seven times higher. WHO estimates that 5% of all cervical cancer cases are attributable to HIV, which is common in parts of the region.

None of the seven GBD super-regions is on course to reach the WHO elimination threshold by 2050 if current trends continue. WHO defines elimination as four or fewer new cases per 100,000 women a year.

What the forecast assumes

The GBD team's projections carry current trends forward. They leave out the effect of future HPV vaccination programmes, according to the Nature Asia press release on the study. Its authors also flag gaps in the availability and quality of data, particularly in low- and middle-income countries. So the figures describe the path the world is on today, and countries can still change it. The authors call for wider access to HPV vaccination, screening and treatment.

What reduces the risk of cervical cancer

Persistent infection with high-risk types of human papillomavirus (HPV) causes almost all cervical cancers, says the WHO cervical cancer fact sheet. Two types, HPV 16 and 18, cause around 76% of cases. Precancer usually takes 15 to 20 years to become cancer, which leaves time to find and treat it.

Women vaccinated before 17 had an 88% lower risk of cervical cancer in a Swedish study of almost 1.7 million women. Risk was halved in women vaccinated between 17 and 30. In Scotland, Public Health Scotland researchers found no cervical cancer cases among fully vaccinated women who had their first dose at 12 or 13.

WHO prioritises vaccination for girls aged 9 to 14, before they become sexually active. Its updated schedule allows one or two doses for girls and young women aged 9 to 20. People with weakened immune systems, including those living with HIV, should have at least two doses, and three where possible.

WHO advises women to have a high-performance test, such as an HPV test, every five to 10 years from age 30. Screening finds precancer before it turns into cancer. Women living with HIV are six times more likely to develop cervical cancer than the general population. WHO advises them to start screening at 25 and repeat it every three to five years.

Self-collected samples for HPV testing are as reliable as samples taken by a health worker, WHO says. Women who find a clinic examination hard to reach or uncomfortable can ask whether self-sampling is offered. When screening finds precancer, WHO lists thermal ablation, cryotherapy and loop excision as ways to destroy or remove the abnormal cells.

Smoking is among the factors WHO says help an HPV infection progress. It names not smoking, condom use and voluntary male circumcision as further protection. WHO also advises women to see a health worker about unusual bleeding between periods, after sex or after menopause. Increased or foul-smelling discharge, and persistent pain in the back, legs or pelvis, also need checking.

Where prevention is working

Australia expects to become the first country to eliminate cervical cancer, by 2035, according to the Australian Government. Its incidence fell to 6.3 per 100,000 in 2021. That year, no woman under 25 was diagnosed with cervical cancer, a first since records began in 1982.

India began a national single-dose HPV programme in February, Gavi reported. It targets about 11.5 million girls aged 14, with free vaccination at government facilities. India accounts for nearly 25% of the world's cervical cancer deaths, according to WHO's 2022 cancer estimates cited in the same report.

Fifteen countries added HPV vaccine to their programmes in 2025, WHO and UNICEF coverage estimates show. They include China, Ghana, Nepal and Pakistan. Yet only 33% of eligible girls aged 9 to 14 received a first dose that year. About 43.6 million girls were missed, and 22.8 million of them live in countries without the vaccine in their programme.

Khyber Pakhtunkhwa, in north-west Pakistan, planned to vaccinate about 2.93 million girls aged 9 to 14, the Associated Press of Pakistan reported. The campaign was set to run from 2 to 14 November. The province follows Punjab, Sindh, Islamabad and Azad Jammu and Kashmir. More than 13 million girls were eligible there in 2025, according to Gavi.

The 2030 targets

WHO's elimination strategy sets three targets for 2030. It aims for 90% of girls to receive HPV vaccine by age 15. It wants 70% of women screened with a high-performance test by 35, and again by 45. A third target is treatment for 90% of women with precancer or cancer. With first-dose coverage at 33% of eligible girls in 2025, the vaccination target remains far off for most countries.

This content is for information only and does not replace advice from a qualified health professional.

Get the week's essential women's health journalism

Evidence-based reporting, delivered to your inbox every week. No hype, no fads.